異常感覚（パレステジア）治療の世界市場

異常感覚（パレステジア）治療の世界市場は2030年までに61億米ドルに達する見込み

2024年に54億米ドルと推定される異常感覚（パレステジア）治療の世界市場は、2024～2030年の分析期間にCAGR 2.1％で成長し、2030年には61億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫抑制剤は、CAGR 1.7%を記録し、分析期間終了時には30億米ドルに達すると予測されます。抗けいれん薬セグメントの成長率は、分析期間中CAGR 1.8％と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 4.0％で成長予測

米国の異常感覚（パレステジア）治療市場は2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8％と1.5％と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界の異常感覚（パレステジア）治療市場- 主要動向と促進要因まとめ

異常感覚（パレステジア）が神経・疼痛管理治療薬の注目領域として台頭しているのはなぜか？

異常感覚（パレステジア）は、末梢神経障害、糖尿病、多発性硬化症、脊髄損傷、化学療法による神経損傷など、さまざまな基礎疾患との関連により、臨床的に重要性を増しています。これらの疾患、特に糖尿病性ニューロパチーや自己免疫性神経障害の罹患率が上昇するにつれて、知覚障害はもはや良性の症状としてではなく、むしろ標的を絞った治療介入が必要な慢性的な症状として捉えられるようになっています。

異常感覚（パレステジア）がQOLや日常生活に与える影響が認識されるようになったことで、治療は対症療法的なマスキングから包括的で集学的な管理へとシフトしています。現在では、神経科医、疼痛専門医、プライマリケア提供者が協力して、原因となる病態を特定し、症状の重症度を定量化し、オーダーメイドのレジメンを実施しています。この市場の拡大は、老年人口の増加、がん治療による神経毒性の増加、異常感覚（パレステジア）と他の神経機能障害を区別する診断法の改善によってさらに促進されます。長期的な緩和と疾患修飾アプローチに対するアンメット・ニーズは、製薬会社や医療機器メーカーの関心を集め続けています。

異常感覚（パレステジア）に対する薬理学的および非薬理学的介入はどのように進化しているか？

現在の異常感覚（パレステジア）治療では、薬物療法、理学的リハビリテーション、そして場合によっては神経調節が組み合わされています。プレガバリンやガバペンチンなどの抗けいれん薬、デュロキセチンやアミトリプチリンなどの抗うつ薬、カプサイシンやリドカインパッチなどの外用薬は、依然として最前線の薬物療法です。これらの薬剤は神経信号伝達に作用し、鎮静や依存を誘発することなく、亢進した感覚経路を減衰させることを目的としています。徐放性製剤や併用療法の進歩により、忍容性とアドヒアランスが改善されつつあります。

非薬理学的治療もまた、特に慢性感覚麻痺が難治性であったり、薬物療法に耐えられない場合に支持を集めています。経皮的電気神経刺激（TENS）、脊髄刺激装置（SCS）、理学療法は、神経刺激を軽減し、感覚統合を高める代替療法です。慢性症状の心理的負担に対処するために、認知行動療法（CBT）が取り入れられています。低レベルレーザー療法やパルス電磁場療法などの新しい技術は、初期の研究で有望視されています。これらの複合的な戦略は、急性症状の抑制から全体的で長期的な管理へのシフトを反映しています。

異常感覚（パレステジア）管理の市場力学に影響を与えている患者集団とヘルスケアシステムは？

糖尿病患者は、異常感覚（パレステジア）を経験する患者集団の中で最大かつ最も急速に増加している集団であり、特に長期間にわたって血糖値のコントロールが不十分な患者が多いです。神経毒性薬剤（例/ プラチナ系薬剤、タキサン系薬剤）による化学療法を受けている腫瘍患者もまた、重要なコホートを形成しています。脊髄損傷、多発性硬化症、反復性疲労損傷のある患者-特に高齢労働者-は、慢性的な感覚障害を訴えることが多いです。おそらく、疼痛報告率が高く、自己免疫疾患の有病率が高いためであろう。

北米は、疼痛管理のインフラがしっかりしており、薬物療法や医療機器に保険が適用され、神経障害性疾患に対する認識が高いため、診断と治療においてリードしています。欧州は、非オピオイド鎮痛経路と統合神経学的ケアを重視する傾向が強まっており、その後に続いています。アジア太平洋は、糖尿病有病率の増加と神経内科専門医へのアクセス拡大により、市場が急成長しています。これとは対照的に、ラテンアメリカやアフリカの一部では、過小診断や専門医へのアクセスが限られていることが、ヘルスケア支援や市場浸透の課題であると同時にチャンスでもあります。

異常感覚（パレステジア）治療市場の長期的な成長と革新の原動力は？

異常感覚（パレステジア）治療市場の成長の原動力は、疾患有病率の増加、臨床的認知度の向上、非オピオイド、マルチモーダル疼痛管理に対する需要の高まりです。神経障害性疼痛の研究開発に対する規制当局の後押しや、脊髄刺激装置のようなデバイスに対する有利な償還政策が、治療の選択肢を広げています。医薬品開発企業は、ナトリウムチャネル遮断薬、神経炎症調節薬、忍容性プロファイルを改善した次世代SNRIを模索しています。神経調節の企業は、低侵襲のインプラントやウェアラブルな生体電気デバイスを改良しています。

症状追跡アプリや遠隔治療プラットフォームを含むデジタルヘルスツールは、患者の自己モニタリングと臨床医のフィードバックループを可能にしています。遺伝的、電気生理学的、心理社会的マーカーによって導かれる個別化された治療アルゴリズムは、転帰を向上させるためにテストされています。ヘルスケアシステムが個別化ケアと慢性疾患管理に向かう中、異常感覚（パレステジア）は負担が大きく、イノベーションの可能性が高い治療領域として注目されています。長期的な成功は、専門領域を超えた連携、患者の関与、そして薬理学と医療技術の両方における継続的な進歩にかかっています。

セグメント

治療タイプ（免疫抑制剤、抗けいれん剤、局所クリーム、抗ウイルス剤）;適応症（放射線障害適応症、神経障害適応症）;エンドユーザー（病院薬局エンドユーザー、小売薬局エンドユーザー、オンライン薬局エンドユーザー）

調査対象企業の例（注目の48社）

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boston Scientific Corporation
• Eli Lilly and Company
• EnteroMedics Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Medtronic plc
• Merck & Co., Inc.
• Nevro Corp.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Smith & Nephew plc
• Stimwave LLC
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Paresthesia Treatment Market to Reach US$6.1 Billion by 2030

The global market for Paresthesia Treatment estimated at US$5.4 Billion in the year 2024, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Anticonvulsants segment is estimated at 1.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 4.0% CAGR

The Paresthesia Treatment market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Paresthesia Treatment Market - Key Trends & Drivers Summarized

Why Is Paresthesia Emerging as a Focus Area in Neurological and Pain Management Therapeutics?

Paresthesia, characterized by abnormal sensations such as tingling, prickling, numbness, or burning-often in the extremities-is gaining clinical significance due to its association with a wide range of underlying conditions including peripheral neuropathy, diabetes, multiple sclerosis, spinal injuries, and chemotherapy-induced nerve damage. With rising incidences of these conditions, particularly diabetic neuropathy and autoimmune neurological disorders, paresthesia is no longer viewed as a benign symptom but rather a chronic manifestation requiring targeted therapeutic intervention.

The growing recognition of paresthesia’s impact on quality of life and daily function has shifted treatment from symptomatic masking to comprehensive, multidisciplinary management. Neurologists, pain specialists, and primary care providers now collaborate to identify causative pathologies, quantify symptom severity, and implement tailored regimens. This market’s expansion is further driven by the rising geriatric population, increased neurotoxicity from cancer therapies, and improved diagnostics that help distinguish paresthesia from other neurological dysfunctions. The unmet need for long-term relief and disease-modifying approaches continues to generate interest from pharmaceutical and device manufacturers alike.

How Are Pharmacological and Non-Pharmacological Interventions Evolving to Address Paresthesia?

Current paresthesia treatment involves a combination of pharmacological therapies, physical rehabilitation, and, in certain cases, neuromodulation. Anticonvulsants such as pregabalin and gabapentin, antidepressants including duloxetine and amitriptyline, and topical agents like capsaicin or lidocaine patches remain frontline pharmaceutical options. These agents act on nerve signal transmission, aiming to dampen hyperactive sensory pathways without inducing sedation or dependency. Advances in slow-release formulations and combination therapies are improving tolerability and adherence.

Non-pharmacological treatments are also gaining traction, particularly in cases where chronic paresthesia is refractory or medication intolerant. Transcutaneous electrical nerve stimulation (TENS), spinal cord stimulators (SCS), and physical therapy regimens offer alternatives that reduce nerve irritation and enhance sensory integration. Cognitive-behavioral therapy (CBT) is being incorporated to address the psychological burden of chronic symptoms. Emerging techniques such as low-level laser therapy and pulsed electromagnetic field therapy show promise in early studies. These multimodal strategies reflect a shift from acute symptom suppression to holistic, long-term management.

Which Patient Populations and Healthcare Systems Are Influencing Market Dynamics in Paresthesia Management?

Diabetic patients represent the largest and fastest-growing population experiencing paresthesia, especially those with long-standing, poorly controlled blood glucose levels. Oncology patients undergoing chemotherapy with neurotoxic agents (e.g., platinum-based drugs, taxanes) also form a significant cohort. Individuals with spinal cord injury, multiple sclerosis, or repetitive strain injuries-particularly among aging workers-frequently report chronic paresthesia. Women tend to seek treatment more often, possibly due to higher pain reporting rates and autoimmune disease prevalence.

North America leads in diagnosis and treatment due to its robust pain management infrastructure, insurance coverage for pharmacotherapy and devices, and strong awareness of neuropathic conditions. Europe follows closely, with growing emphasis on non-opioid pain pathways and integrated neurological care. Asia-Pacific is experiencing rapid market growth due to increasing prevalence of diabetes and expanding access to neurology specialists. In contrast, underdiagnosis and limited access to specialist care in parts of Latin America and Africa present both a challenge and an opportunity for healthcare outreach and market penetration.

What Is Fueling Long-Term Growth and Innovation in the Paresthesia Treatment Market?

The growth in the paresthesia treatment market is driven by increased disease prevalence, improved clinical recognition, and a rising demand for non-opioid, multimodal pain management. Regulatory encouragement for neuropathic pain R&D, along with favorable reimbursement policies for devices like spinal stimulators, is expanding therapeutic options. Drug developers are exploring sodium channel blockers, neuroinflammation modulators, and next-generation SNRIs with improved tolerability profiles. Neuromodulation companies are refining minimally invasive implants and wearable bioelectric devices.

Digital health tools, including symptom tracking apps and remote therapy platforms, are enabling patient self-monitoring and clinician feedback loops. Personalized treatment algorithms-guided by genetic, electrophysiological, and psychosocial markers-are being tested to enhance outcomes. As healthcare systems move toward individualized care and chronic disease management, paresthesia is gaining attention as a therapeutic domain with both high burden and high potential for innovation. Long-term success will depend on cross-specialty collaboration, patient engagement, and continued advancements in both pharmacology and medical technology.

SCOPE OF STUDY:

The report analyzes the Paresthesia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Immunosuppressants, Anticonvulsants, Topical Creams, Antivirals); Indication (Radiculopathy Indication, Neuropathy Indication); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online Pharmacies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boston Scientific Corporation
• Eli Lilly and Company
• EnteroMedics Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Medtronic plc
• Merck & Co., Inc.
• Nevro Corp.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Smith & Nephew plc
• Stimwave LLC
• Stryker Corporation
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Paresthesia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Diabetic Neuropathy and Cervical Spine Disorders Propels Demand for Paresthesia Treatments
  • Expansion of Neuromodulation Therapies Strengthens Business Case for Spinal Cord Stimulators
  • Increased Diagnosis of Peripheral Nerve Compression Throws the Spotlight on Early Intervention Protocols
  • Integration of Pharmacogenomics in Pain Management Supports Personalized Treatment of Paresthesia
  • Availability of Topical Agents and Transdermal Therapies Enhances Non-Invasive Management Options
  • Rising Adoption of Electrical Nerve Stimulation Devices Supports Home-Based Paresthesia Relief
  • Growth in Post-Surgical and Chemotherapy-Induced Paresthesia Expands Application Across Care Pathways
  • Increased Focus on Sensory Function Restoration Drives Innovation in Targeted Therapy Approaches
  • Emergence of AI-Enabled Pain Scoring Systems Enhances Diagnosis and Treatment Monitoring
  • Development of Non-Opioid Analgesics and Anticonvulsants Strengthens Safety Profiles in Long-Term Use
  • Expansion of Clinical Trials for TRPV1 and Sodium Channel Blockers Spurs Drug Innovation
  • Rise in Geriatric Neuropathy-Linked Paresthesia Drives High-Incidence Market Growth
  • Adoption of Lifestyle and Ergonomic Modifications Generates Demand for Complementary Therapies
  • Collaborations Between Pain Clinics and Rehab Centers Support Multidisciplinary Treatment Models
  • Challenges in Measuring Sensory Deficits Highlight Need for Standardized Diagnostic Protocols
  • Digital Patient-Reported Outcome Tracking Enhances Real-World Evidence Collection
  • Regulatory Support for Neuropathic Pain Medications Improves Market Access for Approved Therapies
  • Growing Awareness Through Patient Education Campaigns Spurs Early Treatment Uptake
  • Limitations in Existing Treatment Efficacy Create Demand for Combination Therapy Pathways
  • Increasing Payer Recognition of Chronic Paresthesia Supports Reimbursement-Driven Market Expansion
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Paresthesia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Paresthesia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Paresthesia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Paresthesia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Topical Creams by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Topical Creams by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Topical Creams by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Radiculopathy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Radiculopathy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Radiculopathy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Neuropathy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Neuropathy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Neuropathy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Paresthesia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Paresthesia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Paresthesia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Paresthesia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Paresthesia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Paresthesia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Paresthesia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Paresthesia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Paresthesia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Paresthesia Treatment by Treatment Type - Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Paresthesia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Immunosuppressants, Anticonvulsants, Topical Creams and Antivirals for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Paresthesia Treatment by Indication - Radiculopathy Indication and Neuropathy Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Paresthesia Treatment by Indication - Percentage Breakdown of Value Sales for Radiculopathy Indication and Neuropathy Indication for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Paresthesia Treatment by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Paresthesia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION